The company shared new data on PORT-7, a selective A2B receptor inhibitor, showing significant tumor growth inhibition in a mesothelioma model.
Under the terms of a proposed deal, Immunova, or its affiliate, would acquire the entire share capital of Portage subsidiary iOx Therapeutics.
Portage Biotech announces Nasdaq non-compliance notice; plans to submit compliance strategy by January 24, 2025.Quiver AI SummaryPortage Biotech Inc. has received a notice from Nasdaq indicating that it...
Portage Biotech reports a net loss and continues exploring strategic alternatives while pausing a key clinical trial.Quiver AI SummaryPortage Biotech Inc. reported its financial results for the fiscal...
Portage Biotech Inc. (NASDAQ: PRTG) shares stumbled Friday, as the Westport, Conn.-based company a clinical-stage ...
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now...
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now...
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stock...
Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob...
Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data supporting its...